CMMC for Biomedical Manufacturers: Protecting Intellectual Property and CUI in the Life-Sciences Supply Chain

Why Biomedical Manufacturers Are in Scope for CMMC

Biomedical manufacturers, medical device firms, and life-sciences contractors that support DoD programs are subject to CMMC requirements. This includes companies developing medical countermeasures, trauma care technology, wearable soldier health monitoring systems, and defense-related pharmaceutical research.

If your organization receives DoD contracts that involve Controlled Unclassified Information (CUI), you are required to comply with CMMC Level 2 and all 110 controls in NIST SP 800-171. The fact that your core business is healthcare technology rather than weapons systems does not change your compliance obligations.

With CMMC Phase 2 mandatory C3PAO assessments beginning November 10, 2026, biomedical manufacturers that have not started their preparation are running out of time.

What CUI Looks Like in a Life-Sciences Environment

CUI in a biomedical context can take many forms. Understanding what needs to be protected is the first step in scoping your CMMC environment correctly:

• ✓Defense-funded research data: Results, protocols, and datasets from DoD-sponsored studies on soldier health, battlefield medicine, or military-relevant biotechnology.
• ✓Technical specifications: Design files, engineering drawings, and specifications for medical devices or equipment procured by the DoD.
• ✓Export-controlled research: Data subject to ITAR or EAR that overlaps with your DoD work.
• ✓Contract-related information: Pricing, subcontractor lists, and supply chain details tied to DoD contracts.

One of the most common mistakes biomedical firms make is assuming their CUI environment is limited to a single server or file share. In practice, CUI often flows across email, collaboration platforms, lab information management systems, and shared research databases, each of which must be included in your compliance scope.

Unique Compliance Challenges for Biomedical Firms

Biomedical manufacturers face several compliance challenges that are different from those of a traditional defense contractor:

• ✓Dual-use environments: Research infrastructure often serves both commercial and defense clients. Separating CUI from non-CUI data in a shared lab environment requires careful scoping and often a dedicated enclave.
• ✓Regulated equipment: Laboratory instruments, medical devices under FDA oversight, and clinical data systems may not support the access controls, audit logging, or encryption required by NIST SP 800-171 without significant configuration or replacement.
• ✓Research collaboration: Sharing data with academic partners, clinical research organizations, or overseas collaborators creates CUI handling risks that must be addressed through flow-down requirements and data sharing agreements.
• ✓IP sensitivity: Biomedical firms often hold significant intellectual property that is not classified but is highly sensitive. CMMC controls provide a framework for protecting this IP from nation-state adversaries who actively target defense-adjacent life-sciences research.

Protecting Research Data and Intellectual Property

Nation-state cyber actors, particularly those targeting US defense and dual-use research, have a documented history of attacking biomedical and life-sciences firms. Your intellectual property, including proprietary formulations, device designs, and clinical research data, represents a target that adversaries will pursue through phishing, social engineering, and network intrusion.

CMMC Level 2 controls directly address the most common attack vectors used against biomedical firms:

• ✓Multi-factor authentication requirements close the credential theft gap exploited by spear-phishing campaigns.
• ✓Access control and least-privilege policies limit the blast radius when a single account is compromised.
• ✓Encryption requirements protect research data at rest and in transit, even if an attacker gains access to a storage system.
• ✓Incident response and continuous monitoring controls ensure that intrusions are detected and contained quickly.

Building a CMMC-Compliant Environment for Life Sciences

The most practical approach for many biomedical manufacturers is to build a CMMC-compliant enclave: a dedicated, segmented environment where all CUI-related work takes place. This enclave approach limits the scope of your compliance program and avoids the need to apply NIST controls to your entire research network.

Key steps for biomedical firms getting started:

• ✓Conduct a CUI flow analysis to map where controlled data enters, moves through, and exits your organization.
• ✓Scope your enclave tightly by identifying the minimum set of systems that must touch CUI and isolating them from general research infrastructure.
• ✓Review subcontractor and research partner data sharing arrangements for CMMC flow-down obligations.
• ✓Engage a CMMC Registered Practitioner Organization (RPO) with life-sciences experience to guide your gap assessment and remediation. Small firms may qualify for a free assessment through the CMMC Grants program.